Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
This study is testing a new cancer-killing virus combined with standard immunotherapy against other standard treatments for advanced skin cancer. Researchers want to find a better treatment option for patients whose cancer has kept growing after previous therapies.
You might be able to join if you are 12 years or older with advanced skin cancer (cutaneous melanoma) that cannot be removed by surgery and has grown despite previous immunotherapy treatments. Certain health conditions, like active infections or specific types of melanoma, mean you cannot participate.
Participants will be randomly assigned to receive either the new virus therapy combined with an immunotherapy drug, or a standard treatment chosen by their doctor. Your health team will closely monitor you and your cancer throughout the study to see how well the treatment works.
The study is currently recruiting participants at multiple locations, including sites in Arizona and California. Your study doctor can give you more details about the exact location closest to you.
- 1Testing a new cancer-killing virus combined with immunotherapy
- 2For patients with advanced skin cancer whose previous treatments stopped working
- 3Currently recruiting participants at select locations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.